SG11201606597QA - Multimeric fc proteins - Google Patents

Multimeric fc proteins

Info

Publication number
SG11201606597QA
SG11201606597QA SG11201606597QA SG11201606597QA SG11201606597QA SG 11201606597Q A SG11201606597Q A SG 11201606597QA SG 11201606597Q A SG11201606597Q A SG 11201606597QA SG 11201606597Q A SG11201606597Q A SG 11201606597QA SG 11201606597Q A SG11201606597Q A SG 11201606597QA
Authority
SG
Singapore
Prior art keywords
multimeric
proteins
Prior art date
Application number
SG11201606597QA
Other languages
English (en)
Inventor
Farnaz Fallah-Arani
Robert Anthony Griffin
David Paul Humphreys
Shirley Jane Peters
Bryan John Smith
Paul Edward Stephens
Original Assignee
Ucb Biopharma Sprl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB201403913A external-priority patent/GB201403913D0/en
Priority claimed from GB201403912A external-priority patent/GB201403912D0/en
Priority claimed from GB201405952A external-priority patent/GB201405952D0/en
Priority claimed from GB201412646A external-priority patent/GB201412646D0/en
Application filed by Ucb Biopharma Sprl filed Critical Ucb Biopharma Sprl
Publication of SG11201606597QA publication Critical patent/SG11201606597QA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/528—CH4 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
SG11201606597QA 2014-03-05 2015-03-05 Multimeric fc proteins SG11201606597QA (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB201403913A GB201403913D0 (en) 2014-03-05 2014-03-05 Proteins
GB201403912A GB201403912D0 (en) 2014-03-05 2014-03-05 Proteins
GB201405952A GB201405952D0 (en) 2014-04-02 2014-04-02 Proteins
GB201412646A GB201412646D0 (en) 2014-07-16 2014-07-16 Proteins
PCT/EP2015/054687 WO2015132364A1 (en) 2014-03-05 2015-03-05 Multimeric fc proteins

Publications (1)

Publication Number Publication Date
SG11201606597QA true SG11201606597QA (en) 2016-09-29

Family

ID=52629578

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201606597QA SG11201606597QA (en) 2014-03-05 2015-03-05 Multimeric fc proteins

Country Status (15)

Country Link
US (1) US11352414B2 (pt)
EP (1) EP3114143B1 (pt)
JP (1) JP6851200B2 (pt)
KR (1) KR20160130463A (pt)
CN (1) CN106068274A (pt)
AU (1) AU2015226100B2 (pt)
BR (1) BR112016020368A2 (pt)
CA (1) CA2939198A1 (pt)
IL (1) IL247096A0 (pt)
MX (1) MX2016010951A (pt)
RU (1) RU2016139006A (pt)
SG (1) SG11201606597QA (pt)
TW (1) TW201619188A (pt)
UY (1) UY36021A (pt)
WO (1) WO2015132364A1 (pt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3114143B1 (en) 2014-03-05 2020-07-08 UCB Biopharma SRL Multimeric fc proteins
WO2015168643A2 (en) 2014-05-02 2015-11-05 Momenta Pharmaceuticals, Inc. Compositions and methods related to engineered fc constructs
EP3303380B1 (en) 2015-06-02 2020-01-15 Novo Nordisk A/S Insulins with polar recombinant extensions
GB201511787D0 (en) * 2015-07-06 2015-08-19 Ucb Biopharma Sprl Proteins
GB201513033D0 (en) * 2015-07-23 2015-09-09 Ucb Biopharma Sprl Proteins
KR20240042137A (ko) 2015-07-24 2024-04-01 글리크닉 인코포레이티드 향상된 상보체 결합을 갖는 규칙적으로 다형체화된 면역글로불린 fc 조성물을 생성하기 위한 인간 단백질 단편의 융합 단백질
MA43348A (fr) 2015-10-01 2018-08-08 Novo Nordisk As Conjugués de protéines
BR112018014668A2 (pt) * 2016-01-27 2018-12-11 Csl Behring Recombinant Facility Ag multímeros de fc de igg recombinante
GB201607979D0 (en) * 2016-05-06 2016-06-22 Liverpool School Tropical Medicine Monomeric proteins and uses thereof
CN109963869A (zh) 2016-05-23 2019-07-02 动量制药公司 与经改造的Fc构建体相关的组合物和方法
US11034775B2 (en) 2016-06-07 2021-06-15 Gliknik Inc. Cysteine-optimized stradomers
EP3487534A4 (en) 2016-07-22 2020-03-25 Gliknik Inc. FUSION PROTEINS FROM HUMAN PROTEIN FRAGMENTS FOR THE PRODUCTION OF MULTIMERIZED IMMUNOGLOBULIN FC COMPOSITIONS WITH INCREASED FC RECEPTOR BINDING
WO2018107082A1 (en) 2016-12-09 2018-06-14 Gliknik Inc. Methods of treating inflammatory disorders with multivalent fc compounds
AU2017371179B2 (en) 2016-12-09 2022-07-14 Gliknik Inc. Manufacturing optimization of GL-2045, a multimerizing stradomer
JP7146771B2 (ja) 2017-01-06 2022-10-04 モメンタ ファーマシューティカルズ インコーポレイテッド 操作されたＦｃコンストラクトに関する組成物及び方法
CN113201071A (zh) * 2017-03-28 2021-08-03 礼进生物医药科技（上海）有限公司 用于增强肿瘤微环境中免疫应答的治疗剂和方法
MA49339A (fr) 2017-04-05 2020-02-12 Novo Nordisk As Conjugués insuline-fc à extension oligomère
KR101913743B1 (ko) 2017-04-07 2018-11-01 국민대학교 산학협력단 혈중 반감기 연장을 위한 항체 Fc 변이체들
JP2020522266A (ja) * 2017-06-05 2020-07-30 ヤンセン バイオテツク，インコーポレーテツド 非対称なｃｈ２−ｃｈ３領域の変異を有する、操作された多重特異性抗体及び他の多量体タンパク質
CN112004550A (zh) * 2017-12-14 2020-11-27 康诺贝林伦瑙有限公司 用于治疗视神经脊髓炎的重组IgG Fc多聚体
WO2019175605A1 (en) * 2018-03-16 2019-09-19 Liverpool School Of Tropical Medicine Chimeric fc receptor binding proteins and uses thereof
KR102232659B1 (ko) * 2018-07-16 2021-03-26 전북대학교 산학협력단 항원전달용 폴리펩타이드, 이를 포함하는 Fc-융합 단백질 및 이의 용도
CN113271972A (zh) * 2018-11-14 2021-08-17 Jn生物科学有限责任公司 用于替代IVIG的多聚体杂交Fc蛋白
BR112022003713A2 (pt) 2019-09-13 2022-08-09 CSL Behring Lengnau AG Multímeros de fc de igg recombinantes para o tratamento de doenças renais mediadas por imunocomplexo
WO2021111007A1 (en) * 2019-12-06 2021-06-10 CSL Behring Lengnau AG Stable compositions of fc multimers
GB2595299B (en) * 2020-05-21 2022-08-03 Mabsolve Ltd Modified immunoglobulin FC regions
CN115724985A (zh) * 2021-08-27 2023-03-03 三生国健药业（上海）股份有限公司 一种cdc平台抗体
WO2023239940A1 (en) * 2022-06-10 2023-12-14 Research Development Foundation Engineered fcriib selective igg1 fc variants and uses thereof

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US20020147326A1 (en) * 1996-06-14 2002-10-10 Smithkline Beecham Corporation Hexameric fusion proteins and uses therefor
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
US6114515A (en) 1997-08-25 2000-09-05 Smithkline Beecham Corporation PIGRL-1, a member of immunoglobulin gene superfamily
GB9720054D0 (en) 1997-09-19 1997-11-19 Celltech Therapeutics Ltd Biological products
DK1068241T3 (da) 1998-04-02 2008-02-04 Genentech Inc Antistofvarianter og fragmenter deraf
US6284536B1 (en) 1998-04-20 2001-09-04 The Regents Of The University Of California Modified immunoglobin molecules and methods for use thereof
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
MY129566A (en) 1999-01-19 2007-04-30 Nestle Sa A hypoallergenic composition containing tolerogenic peptides inducing oral tolerance
US6475749B1 (en) 1999-08-11 2002-11-05 The Regents Of The University Of California Rh hybrid antibody
DE10001372A1 (de) 2000-01-14 2001-08-02 Deutsches Krebsforsch Anti-CD3-Einzelketten-Antikörper mit humanem Cmu3- und Cmu4- Domänen
MXPA03008031A (es) 2001-03-07 2003-12-04 Merck Patent Gmbh Tecnologia de expresion para proteinas que contienen porcion de anticuerpo isotipo hibrida.
KR100453877B1 (ko) 2001-07-26 2004-10-20 메덱스젠 주식회사 연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 ＴＮＦＲ/Ｆｃ 융합 단백질, 상기 단백질을 코딩하는 ＤＮＡ, 상기 ＤＮＡ를 포함하는벡터, 및 상기 벡터에 의한 형질전환체
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
EP2364996B1 (en) 2002-09-27 2016-11-09 Xencor Inc. Optimized FC variants and methods for their generation
US8388955B2 (en) * 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
CA2527020A1 (en) 2003-07-01 2005-01-13 Celltech R & D Limited Modified antibody fab fragments
US20060134105A1 (en) 2004-10-21 2006-06-22 Xencor, Inc. IgG immunoglobulin variants with optimized effector function
WO2005063815A2 (en) 2003-11-12 2005-07-14 Biogen Idec Ma Inc. Fcϝ receptor-binding polypeptide variants and methods related thereto
SI2471813T1 (sl) 2004-07-15 2015-03-31 Xencor, Inc. Optimirane Fc variante
KR101571027B1 (ko) 2006-06-12 2015-11-23 이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 효과기 기능을 갖는 단일쇄 다가 결합 단백질
JPWO2008032833A1 (ja) 2006-09-14 2010-01-28 株式会社医学生物学研究所 Ａｄｃｃ活性を増強させた抗体及びその製造方法
BRPI0811857A2 (pt) 2007-05-14 2014-10-21 Biogen Idec Inc Regiões fc (scfc) de cadeia simples, polipeptídeos de aglutinação que as compreendem e métodos relacionados.
PL2185589T3 (pl) * 2007-06-01 2016-09-30 Środki wiążące receptor regionu stałego Fc immunoglobuliny
KR20100135808A (ko) 2008-03-13 2010-12-27 바이오테스트 아게 질병 치료제
JP2012515556A (ja) 2009-01-23 2012-07-12 バイオジェン・アイデック・エムエイ・インコーポレイテッド 低下したエフェクタ機能を有する安定化Ｆｃポリペプチドおよび使用方法
CA2778673A1 (en) 2009-10-27 2011-05-05 Karen Margrete Miller Function modifying nav 1.7 antibodies
GB0922209D0 (en) * 2009-12-18 2010-02-03 Univ Nottingham Proteins, nucleic acid molecules and compositions
PL2598533T3 (pl) 2010-07-28 2019-07-31 Gliknik Inc. Białka fuzyjne naturalnych fragmentów białka ludzkiego do tworzenia uporządkowanych multimeryzowanych kompozycji Fc immunoglobulin
UA117901C2 (uk) 2011-07-06 2018-10-25 Ґенмаб Б.В. Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
CA2849765C (en) * 2011-09-26 2021-10-19 Jn Biosciences Llc Hybrid constant regions
ES2751386T3 (es) 2011-12-21 2020-03-31 Amgen Inc Polipéptidos Fc variantes con unión potenciada al receptor de Fc neonatal
KR102041412B1 (ko) 2011-12-30 2019-11-11 한미사이언스 주식회사 면역글로불린 Ｆｃ 단편 유도체
US11180572B2 (en) 2012-07-06 2021-11-23 Genmab B.V. Dimeric protein with triple mutations
KR20150037959A (ko) 2012-08-02 2015-04-08 에프. 호프만-라 로슈 아게 단량체 및 다량체 분자의 제조 방법 및 이의 용도
JP2015524821A (ja) * 2012-08-02 2015-08-27 ジェイエヌ バイオサイエンシーズ エルエルシー システイン変異及びμ尾部を介して多量体化した抗体又は融合タンパク質
KR20150058236A (ko) 2012-08-20 2015-05-28 글리크닉 인코포레이티드 항원 결합 및 다가 fc 감마 수용체 결합 활성을 가진 분자
AU2012392760C1 (en) 2012-10-17 2021-08-12 CSL Behring Lengnau AG Immunomodulatory proteins
EP3114143B1 (en) * 2014-03-05 2020-07-08 UCB Biopharma SRL Multimeric fc proteins
SG11201606596PA (en) 2014-03-05 2016-09-29 Ucb Biopharma Sprl Multimeric fc proteins
CN106255704A (zh) 2014-04-16 2016-12-21 Ucb生物制药私人有限公司 多聚体Fc蛋白
WO2015168643A2 (en) 2014-05-02 2015-11-05 Momenta Pharmaceuticals, Inc. Compositions and methods related to engineered fc constructs
AU2016227632A1 (en) 2015-03-05 2017-09-14 Ucb Biopharma Sprl Polymeric Fc proteins and methods of screening to alter their functional characteristics
GB201511787D0 (en) 2015-07-06 2015-08-19 Ucb Biopharma Sprl Proteins

Also Published As

Publication number Publication date
MX2016010951A (es) 2016-11-29
RU2016139006A (ru) 2018-04-05
JP6851200B2 (ja) 2021-03-31
AU2015226100A1 (en) 2016-08-25
TW201619188A (zh) 2016-06-01
CN106068274A (zh) 2016-11-02
WO2015132364A1 (en) 2015-09-11
EP3114143A1 (en) 2017-01-11
JP2017512063A (ja) 2017-05-18
AU2015226100B2 (en) 2020-05-07
CA2939198A1 (en) 2015-09-11
EP3114143B1 (en) 2020-07-08
UY36021A (es) 2015-09-30
KR20160130463A (ko) 2016-11-11
US20170088603A1 (en) 2017-03-30
IL247096A0 (en) 2016-09-29
US11352414B2 (en) 2022-06-07
BR112016020368A2 (pt) 2018-01-23

Similar Documents

Publication Publication Date Title
IL247096A0 (en) proteins fc multimers
IL247246A0 (en) proteins fc multimers
HK1232136A1 (zh) 融合蛋白
PL3702450T3 (pl) Białko
GB201418562D0 (en) Peptides
GB201415344D0 (en) Protein
HRP20182029T1 (hr) Uti-fuzijski proteini
HUE057808T2 (hu) Fehérje visszanyerés
IL248276A0 (en) Carbohydrate binding proteins
PL3099793T3 (pl) Białko
GB201401877D0 (en) Peptides
EP3099320A4 (en) Protein m related immunoglobulin-binding polypeptides
EP3204427A4 (en) Chimeric proteins
SG11201606501PA (en) Nanobody-fluorescent protein fusion
HK1253316A1 (zh) 肽
GB201517390D0 (en) Protein variant analysis
GB201412797D0 (en) Proteins
GB201412648D0 (en) Proteins
GB201412649D0 (en) Proteins
GB201412646D0 (en) Proteins
GB201406894D0 (en) Proteins
GB201414371D0 (en) Protein modification
GB201405955D0 (en) Proteins
GB201405952D0 (en) Proteins
GB201403913D0 (en) Proteins